Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug 27;3(4):oead080.
doi: 10.1093/ehjopen/oead080. eCollection 2023 Jul.

Lipoprotein(a): the enemy that we still don't know how to defeat

Maciej Banach  1   2   3   4
Affiliations
Editorial

Lipoprotein(a): the enemy that we still don't know how to defeat

Maciej Banach. Eur Heart J Open. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: (36 months) Maciej Banach: speakers bureau: Amgen, Daiichi Sankyo, Kogen, KRKA, Polpharma, Novartis, Novo-Nordisk, Pfizer, Sanofi, Teva, Viatris, Zentiva; consultant to Adamed, Amgen, Daichii Sankyo, Esperion, NewAmsterdam, Novartis, Novo-Nordisk, Sanofi; grants from Amgen, Daiichi Sankyo, Sanofi, and Viatris, CMDO at Longevity Group; CMO at Nomi Biotech Corporation.

Figures

Figure 1
Figure 1
The suggested pathway of management with patients with elevated Lp(a) concentration. *The picture of Lp(a) was reprinted and modified from Liu, T et al. Chonnam Med J. 2021, 57, 36–43 (no permission required).
See this image and copyright information in PMC

Comment in

References

    1. Sosnowska B, Surma S, Banach M. Targeted treatment against lipoprotein (a): the coming breakthrough in lipid lowering therapy. Pharmaceuticals (Basel) 2022;15:1573. - PMC - PubMed
    1. Catapano AL, Tokgözoğlu L, Banach M, Gazzotti M, Olmastroni E, Casula M, Ray KK; Lipid Clinics Network Group . Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: a survey among the Lipid Clinics Network. Atherosclerosis 2023;370:5–11. - PubMed
    1. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43:3925–3946. - PMC - PubMed
    1. Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, Gąsior M, Jankowski P, Jóźwiak J, Kłosiewicz-Latoszek L, Kowalska I, Małecki M, Prejbisz A, Rakowski M, Rysz J, Solnica B, Sitkiewicz D, Sygitowicz G, Sypniewska G, Tomasik T, Windak A, Zozulińska-Ziółkiewicz D, Cybulska B. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci 2021;17:1447–1547. - PMC - PubMed
    1. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky ML, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis 2023;374:107–120. - PubMed

Publication types